Literature DB >> 12443673

Emergency response vaccines--a challenge for the public sector and the vaccine industry.

Julie Milstien1, Scott Lambert.   

Abstract

In partnership with industry, WHO has developed a number of strategies to facilitate access to vaccines recommended for use in national immunization programs. These strategies have been necessitated by the increasing fragility of vaccine supply for developing markets. The potential global spread of epidemic disease has made it imperative to expand these efforts. A new concept is proposed, that of essential vaccines, defined as "vaccines of public health importance that should be accessible to all people at risk". Essential vaccines will include emergency response vaccines that have become important due to resurgent outbreaks, threatening global pandemics, and situations where a global emergency immunization response may be needed. While some of the approaches already developed will be applicable to emergency response vaccines, other novel approaches requiring public sector intervention will be necessary. Procurement, financing and allocation of these emergency response vaccines, if left to governments or private individuals based on ability to pay, will threaten equitable access. The challenge will be to ensure development of and equitable access to these vaccines while not threatening the already fragile supply of other essential vaccines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12443673     DOI: 10.1016/s0264-410x(02)00436-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

Review 1.  The development of global vaccine stockpiles.

Authors:  Catherine Yen; Terri B Hyde; Alejandro J Costa; Katya Fernandez; John S Tam; Stéphane Hugonnet; Anne M Huvos; Philippe Duclos; Vance J Dietz; Brenton T Burkholder
Journal:  Lancet Infect Dis       Date:  2015-02-06       Impact factor: 25.071

2.  Vaccination for pandemic influenza and severe acute respiratory syndrome: common issues and concerns.

Authors:  David S Fedson
Journal:  Clin Infect Dis       Date:  2003-06-05       Impact factor: 9.079

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.